Marsters, Jr., Ph.D., Frederic J. De Sauvage, Ph.D., and Jennifer A. Low, M.D., Ph.D.: Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma Basal-cell carcinoma, the most typical skin tumor in the United States, comes with an estimated annual incidence of 0.1 to 0.5 percent.1,2 The condition is largely caused by exposure to ultraviolet radiation, but you can find other risk factors.3,4 Surgery remedies most situations of basal-cell carcinoma, however in a few sufferers there is progression to life-threatening, unresectable, locally advanced5,6 or metastatic7,8 tumors. There is no standard therapy for advanced or metastatic basal-cell carcinoma locally.Shah.
Accuray Incorporated showcases CyberKnife VSI Program at ESTRO Annual Congress Accuray Integrated , a worldwide leader in the field of radiosurgery, today that for the very first time in Europe the company showcased its latest supplying announced, the CyberKnife VSI System, at ESTRO 29; the Annual Congress of the European Society for Therapeutic Oncology and Radiology in Barcelona, Spain. Also featured at this meeting had been multiple presentations demonstrating this system’s best-in-class motion management features for lung cancer care. During a well-attended symposium on movement administration in lung radiosurgery chaired by Pr. Volker Budach, M.D., Ph.D. Clinical study presented through the symposium demonstrated the advantages of CyberKnife radiosurgery in the treating major early stage and metastatic lung cancers, including exceptional disease preservation and control of quality of life.